{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:13:24Z","timestamp":1794276804314,"version":"4.9.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Antibody-drug conjugates (ADCs) are increasingly utilized in patients with solid tumors and hematologic malignancies. However, the adverse ocular toxicity induced by ADCs has not been comprehensively evaluated in real-world clinical settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from April 2019 to March 2024 based on the FDA Adverse Event Reporting System (FAERS) were extracted and analyzed. Disproportionality analysis was used to evaluate the association between ADCs and ocular adverse events (AEs). The median time to onset (TTO) of various ADCs was compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A comprehensive analysis identified 2,686 ocular AEs associated with ADCs. Among these, Tisotumab vedotin had the most positive signals at the preferred terms (PTs) level, followed by trastuzumab emtansine and enfortumab vedotin. In contrast, gemtuzumab ozogamicin demonstrated minimal ocular toxicity signals. Cluster analysis revealed that ADC-related ocular toxicities predominantly manifested as corneal disorders or ocular neuromuscular disorders. The median onset of ocular toxicity varied considerably, with enfortumab vedotin showing the earliest median onset at 12.5 days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study demonstrates the association between ADCs and ocular AEs based on real-world data, providing valuable guidance for clinicians when prescribing ADCs. And we found some important safety signals that have not been mentioned in the label or previous studies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1495137","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T05:10:24Z","timestamp":1734412224000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Heng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gefei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discovery"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21705","article-title":"Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-024-01582-x","article-title":"Economics of antibody drug conjugates (ADCs): innovation, investment and market dynamics","volume":"26","author":"Bhushan","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40265-021-01507-z","article-title":"Ocular toxicity of targeted anticancer agents","volume":"81","author":"Fortes","year":"2021","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.1463","article-title":"Antibody-drug conjugates: A review of cutaneous adverse effects","volume":"91","author":"Saberi","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2024.04.003","article-title":"Gastrointestinal toxicity of antibody drug conjugates (ADCs) in metastatic breast cancer: A pooled analysis","volume":"24","author":"Pedersini","year":"2024","journal-title":"Clin Breast Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01058-9","article-title":"Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA adverse event reporting system","volume":"19","author":"Cecco","year":"2024","journal-title":"Target Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: A review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae177","article-title":"Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies","volume":"29","author":"Dy","year":"2024","journal-title":"Oncologist"},{"key":"B12","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/annonc\/mdw100","article-title":"Ocular toxicities of MEK inhibitors and other targeted therapies","volume":"27","author":"Stjepanovic","year":"2016","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2251380","article-title":"Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies","volume":"22","author":"Raheem","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008518","article-title":"Cardiovascular toxicities associated with bispecific T-cell engager therapy","volume":"12","author":"Sayed","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28671","article-title":"Association of antiviral drugs and their possible mechanisms with DRESS syndrome using data mining algorithms","volume":"95","author":"Sharma","year":"2023","journal-title":"J Med Virol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0146-y","article-title":"Performance of probabilistic method to detect duplicate individual case safety reports","volume":"37","author":"Tregunno","year":"2014","journal-title":"Drug Saf"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01210-2","article-title":"Anti-tumor necrosis factor-alpha therapy and hypoglycemia: A real-world pharmacovigilance analysis","volume":"45","author":"Zhou","year":"2022","journal-title":"Drug Saf"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15361","article-title":"Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System","volume":"88","author":"Dong","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102684","article-title":"Characterization of second primary Malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase","volume":"73","author":"Shen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104398","article-title":"Safety of immune checkpoint inhibitors: An updated comprehensive disproportionality analysis and meta-analysis","volume":"200","author":"Tyagi","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13690","article-title":"Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: A disproportionality analysis","volume":"146","author":"Sharma","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"B27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","article-title":"Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database","volume":"22","author":"Zhou","year":"2024","journal-title":"BMC Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2385497","article-title":"Eye disorders associated with selective serotonin reuptake inhibitors: a real-world disproportionality analysis of FDA adverse event reporting system","author":"Li","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2355335","article-title":"Differences in ocular adverse events associated with phosphodiesterase-5 inhibitors: a real-world pharmacovigilance study","volume":"23","author":"Chen","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15494","article-title":"Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis","volume":"89","author":"Zhao","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2022.110286","article-title":"The Human Eye Transcriptome Atlas: A searchable comparative transcriptome database for healthy and diseased human eye tissue","volume":"114","author":"Wolf","year":"2022","journal-title":"Genomics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40135-024-00322-5","article-title":"Incidence and mitigation of corneal pseudomicrocysts induced by antibody-drug conjugates (ADCs)","volume":"12","author":"Lindgren","year":"2024","journal-title":"Curr Ophthalmol Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2962","article-title":"Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer","volume":"26","author":"Hong","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00844-x","article-title":"A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma","volume":"38","author":"Takahashi","year":"2020","journal-title":"Invest New Drugs"},{"key":"B37","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34848","article-title":"Ocular toxicity associated with anti-HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database","volume":"154","author":"Chen","year":"2024","journal-title":"Int J Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2023.0069","article-title":"Antibody-drug conjugates and ocular toxicity","volume":"39","author":"Jaffry","year":"2023","journal-title":"J Ocul Pharmacol Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2016.02.008","article-title":"New developments for antibody-drug conjugate-based therapeutic approaches","volume":"40","author":"de Goeij","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0481","article-title":"Phase I trials of anti-ENPP3 antibody-drug conjugates in advanced refractory renal cell carcinomas","volume":"24","author":"Thompson","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.4403","article-title":"Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed\/refractory B-cell lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"B44","article-title":"Tissue factor expression in human pterygium","volume":"17","author":"Ando","year":"2011","journal-title":"Mol Vis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2010.184","article-title":"Evidence for enhanced tissue factor expression in age-related macular degeneration","volume":"91","author":"Cho","year":"2011","journal-title":"Lab Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-200101000-00016","article-title":"Expression of the receptor tyrosine kinases, epidermal growth factor receptor, ErbB2, and ErbB3, in human ocular surface epithelia","volume":"20","author":"Liu","year":"2001","journal-title":"Cornea"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-0119","article-title":"Role of erbB2 in corneal epithelial wound healing","volume":"45","author":"Xu","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"18997","DOI":"10.1038\/s41598-019-55460-9","article-title":"Nectin-4 cis-interacts with ErbB2 and its trastuzumab-resistant splice variants, enhancing their activation and DNA synthesis","volume":"9","author":"Kedashiro","year":"2019","journal-title":"Sci Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1495137\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T05:10:32Z","timestamp":1734412232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1495137\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2024.1495137"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1495137","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2024.1495137.s001","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]},"article-number":"1495137"}}